Read by QxMD icon Read

American Journal of Hematology

Fausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, Antonio Spitaleri, Gabriele Gugliotta, Francesco Fabbiano, Isabella Capodanno, Donato Mannina, Marzia Salvucci, Agostino Antolino, Roberto Marasca, Maurizio Musso, Monica Crugnola, Stefana Impera, Elena Trabacchi, Caterina Musolino, Francesco Cavazzini, Giuseppe Mineo, Patrizia Tosi, Carmela Tomaselli, Michele Rizzo, Sergio Siragusa, Miriam Fogli, Riccardo Ragionieri, Alessandro Zironi, Simona Soverini, Giovanni Martinelli, Michele Cavo, Paolo Vigneri, Fabio Stagno, Gianantonio Rosti, Michele Baccarani
Chronic myeloid leukemia (CML) treatment is based on company-sponsored and academic trials testing different tyrosine kinase inhibitors (TKIs) as first-line therapy. These studies included patients selected according to many inclusion-exclusion criteria, particularly age and comorbidities, with specific treatment obligations. In daily clinical practice (real-life), inclusion-exclusion criteria do not exist and the treatment outcome does not only depend on the choice of first-line TKI, but also on second- and third-line TKIs...
October 22, 2016: American Journal of Hematology
Chadi Nabhan, Anthony R Mato, Bruce A Feinberg
No abstract text is available yet for this article.
October 20, 2016: American Journal of Hematology
Yan Dai, Jose Sangerman, Mehdi Nouraie, Aidan D Faller, Patricia Oneal, Angela Rock, Oluwakemi Owoyemi, Xiaomei Niu, Sergei Nekhai, Dashmeet Maharaj, Shauiying Cui, Robert Taylor, Martin Steinberg, Susan Perrine
No abstract text is available yet for this article.
October 20, 2016: American Journal of Hematology
Eva S Laube, Simon Mantha, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A Soff
No abstract text is available yet for this article.
October 20, 2016: American Journal of Hematology
Maa-Ohui Quarmyne, Wei Dong, Rodney Theodore, Sonia Anand, Vaughn Barry, Olufolake Adisa, Iris D Buchanan, James Bost, Robert C Brown, Clinton H Joiner, Peter A Lane
The clinical efficacy of hydroxyurea in patients with sickle cell anemia (SCA) has been well established. However, data about its clinical effectiveness in practice is limited. We evaluated the clinical effectiveness of hydroxyurea in a large pediatric population using a retrospective cohort, pre-post treatment study design to control for disease severity selection bias. The cohort included children with SCA (SS, Sβ(0) thalassemia) who received care at Children's Healthcare of Atlanta (CHOA) and who initiated hydroxyurea in 2009-2011...
October 19, 2016: American Journal of Hematology
Philipp W Raess, Michael J Cascio, Guang Fan, Richard Press, Brian J Druker, Diana Brewer, Stephen E Spurgeon
No abstract text is available yet for this article.
October 19, 2016: American Journal of Hematology
Daniel Greener, Kelly F Henrichs, Jane L Liesveld, Joanna M Heal, Christopher Aquina, Gordon L Phillips, Scott A Kirkley, Laurie A Milner, Majed A Refaai, Jason H Mendler, Jill Szydlowski, Debra Masel, Amy Schmidt, Francis P Boscoe, Maria J Schmymura, Neil Blumberg
No abstract text is available yet for this article.
October 19, 2016: American Journal of Hematology
Tiziano Barbui, Alessandro M Vannucchi, Alessandra Carobbio, Elisa Rumi, Guido Finazzi, Heinz Gisslinger, Marco Ruggeri, Maria Luigia Randi, Mario Cazzola, Alessandro Rambaldi, Bettina Gisslinger, Lisa Pieri, Juergen Thiele, Animesh Pardanani, Ayalew Tefferi
No abstract text is available yet for this article.
October 13, 2016: American Journal of Hematology
David Rizzo, Pierre-Julien Viailly, Sylvain Mareschal, Elodie Bohers, Jean-Michel Picquenot, Dominique Penther, Sydney Dubois, Vinciane Marchand, Philippe Bertrand, Catherine Maingonnat, Pascaline Etancelin, Jean Feuillard, Christian Bastard, Hervé Tilly, Fabrice Jardin, Philippe Ruminy
Little is known on the phylogenetic relationship between diagnostic and relapse clones of Diffuse Large B-Cell Lymphoma (DLBCL). We applied High Throughput Sequencing (HTS) of the VDJ locus of Immunoglobulin Heavy chain (IGHV) on fourteen DLBCL patients with serial samples, including tumor biopsies and/or peripheral blood mononuclear cells (PBMC). Phylogenetic data were consolidated with targeted sequencing and cytogenetics. Phylogeny clearly showed that DLBCL relapse could occur according either an early or a late divergent mode...
October 13, 2016: American Journal of Hematology
Louisa M Lobigs, Pierre-Edouard Sottas, Pitre C Bourdon, Zoran Nikolovski, Mohamed El-Gingo, Evdokia Varamenti, Peter Peeling, Brian Dawson, Yorck O Schumacher
Plasma volume and red cell mass are key health markers used to monitor numerous disease states, such as heart failure, kidney disease or sepsis. Nevertheless, there is currently no practically applicable method to easily measure absolute plasma or red cell volumes in a clinical setting. Here, a novel marker for plasma volume and red cell mass was developed through analysis of the observed variability caused by plasma volume shifts in common biochemical measures, selected based on their propensity to present with low variations over time...
October 13, 2016: American Journal of Hematology
Mrinal M Patnaik, Daniela Barraco, Terra L Lasho, Christy M Finke, Curtis A Hanson, Rhett P Ketterling, Naseema Gangat, Ayalew Tefferi
DNMT3A mutations are seen in ∼5% of patients with chronic myelomonocytic leukemia (CMML) and thus far, have had an indeterminate prognostic impact on survival. We carried out this study to assess the prognostic impact of DNMT3A mutations on a larger informative cohort of CMML patients (n=261). DNMT3A mutations were seen in 6% (n=16); 56% (n=9) male, with a median age of 64 years. Eighty-one % of DNMT3A mutations were missense, with the Arg882 mutational hot spot accounting for 63% of all changes. Five (31%) patients had an abnormal karyotype whereas concurrent gene mutations (SF3B1/SRSF2/U2AF1-56%, TET2-50%, and ASXL1-25%) were seen in all patients...
October 12, 2016: American Journal of Hematology
Yi L Hwa, Qian Shi, Shaji K Kumar, Martha Q Lacy, Morie A Gertz, Prashant Kapoor, Francis K Buadi, Nelson Leung, David Dingli, Ronald S Go, Suzanne R Hayman, Wilson I Gonsalves, Stephen Russell, John A Lust, Yi Lin, S Vincent Rajkumar, Angela Dispenzieri
A preclinical study demonstrated anti-proliferative and apoptotic effect of propranolol on multiple myeloma (MM) cell. Clinical studies suggested that beta blocker (BB) might impact the prognosis of breast, prostate, colorectal, ovarian, lung, and skin cancer. This retrospective study evaluated the effect of BB in MM disease-specific survival (DSS) and overall survival (OS). Among 1971 newly diagnosed MM patients seen at Mayo Clinic between 1995 and 2010, usage of BB and other cardiac (or antihypertensive) medications were abstracted...
October 12, 2016: American Journal of Hematology
Preetesh Jain, Hagop Kantarjian, Elias Jabbour, Rashmi Kanagal-Shamanna, Keyur Patel, Sherry Pierce, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Susan O'Brien, Jorge Cortes
No abstract text is available yet for this article.
October 11, 2016: American Journal of Hematology
Zhihong Hu, Yi Sun, Wei Wang, L Jeffrey Medeiros, Rashmi Kanagal-Shamanna
No abstract text is available yet for this article.
October 11, 2016: American Journal of Hematology
Daniel Xia, Robert P Hasserjian
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are myeloproliferative neoplasms characterized by recurrent somatic mutations in JAK2, CALR, and MPL. This short review addresses 1) the spectrum of mutations seen in PV, ET, and PMF, 2) the emerging genotype-phenotype correlations, 3) the current role of molecular testing in disease classification and management, and 4) several important considerations for selecting an appropriate molecular test. In our view, sequential testing algorithms and simultaneous assessment of multiple mutations by next-generation sequencing are both valid approaches to testing...
October 11, 2016: American Journal of Hematology
H Franklin Bunn
No abstract text is available yet for this article.
October 8, 2016: American Journal of Hematology
Ashley Rosko, Hai-Lin Wang, Marcos de Lima, Brenda Sandmaier, H Jean Khoury, Andrew Artz, Johnathan Brammer, Christopher Bredeson, Sherif Farag, Mohamed Kharfan-Dabaja, Hillard M Lazarus, David I Marks, Rodrigo Martino Bufarull, Joseph McGuirk, Mohamed Mohty, Taiga Nishihori, Ian Nivison-Smith, Armin Rashidi, Olle Ringden, Matthew Seftel, Daniel Weisdorf, Veronika Bachanova, Wael Saber
: Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have poor survival. We examined the effectiveness of reduced intensity conditioning (RIC) hematopoietic cell transplant (HCT) in adults with B-ALL age 55 years and older and explored prognostic factors associated with long-term outcomes. METHODS: Using CIBMTR registry data, we evaluated 273 patients (median age 61, range 55-72) with B-ALL with disease status in CR1 (71%), >CR2 (17%) and Primary Induction Failure (PIF)/Relapse (11%), who underwent RIC HCT between 2001-2012 using mostly unrelated donor (59%) or HLA-matched sibling (32%)...
October 6, 2016: American Journal of Hematology
Abdelhafid Natiq, Philippe A Lysy, Nynke Gillemans, Rianne Schaap, Abdelaziz Sefiani, Saaid Amzazi, Siham Chafai El-Alaoui, Ileana Cantú, Bella Banjanin, Kirsten van Lom, Cornelis L Harteveld, Sjaak Philipsen
No abstract text is available yet for this article.
October 4, 2016: American Journal of Hematology
Nicola Polverelli, Massimo Breccia, Giulia Benevolo, Bruno Martino, Alessia Tieghi, Roberto Latagliata, Elena Sabattini, Mara Riminucci, Laura Godio, Lucia Catani, Maura Nicolosi, Margherita Perricone, Daria Sollazzo, Gioia Colafigli, Anna Campana, Francesco Merli, Umberto Vitolo, Giuliana Alimena, Giovanni Martinelli, Russell E Lewis, Nicola Vianelli, Michele Cavo, Francesca Palandri
Although infectious complications represent a relevant cause of morbidity and mortality in patients with myelofibrosis (MF), little is known about their incidence, outcome and risk factors. We retrospectively evaluated a cohort of 507 MF patients, diagnosed between 1980 and 2014 in five Italian hematology centers, to define the epidemiology of infections and describe the impact of ruxolitinib (RUX) treatment. Overall, 112 patients (22%) experienced 160 infectious events (grade 3-4, 45%) for an incidence rate of 3...
October 4, 2016: American Journal of Hematology
Baruch Wolach, Ronit Gavrieli, Martin de Boer, Karin van Leeuwen, Sivan Berger-Achituv, Tal Stauber, Josef Ben Ari, Menachem Rottem, Yechiel Schlesinger, Galia Grisaru-Soen, Omar Abuzaitoun, Nufar Marcus, Ben Zion Garty, Arnon Broides, Jakov Levy, Polina Stepansky, Amos Etzioni, Raz Somech, Dirk Roos
Chronic granulomatous disease (CGD) is an innate immunodeficiency with a genetic defect of the nicotinamide adenosine dinucleotide phosphate, reduced, oxidase components. This leads to decreased reactive oxygen species (ROS) production, which renders patients susceptible to life-threatening infections. Over the course of 30 years, we diagnosed CGD in 84 patients from 61 families using functional, molecular and genetic studies. The incidence of CGD in Israel is 1.05 per 100,000 live-births in the Jewish population and 1...
October 4, 2016: American Journal of Hematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"